To Explore the Protective Mechanism of Promethazine Against Hippocampal Neuron Injury Based on Network Pharmacology and Experimental Verification

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 Dec 10

PMID 39654167

Authors

Li Bai

Fang Li

Affiliations

Soon will be listed here.

Abstract

This study aims to investigate the effect of promethazine (PMZ) on hippocampal neuronal injury through network pharmacology and in vivo experiments. Network pharmacology: The intersection genes of PMZ and Alzheimer Disease (AD) were obtained, and the core genes of PMZ in AD were screened. The intersection genes were enriched by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. In the in vitro experiment, mouse hippocampal neurons (HT22) were divided into control, glutamate (GLU) model, and GLU + PMZ treatment groups. The control group was given a complete culture medium, the model group was given GLU for 24 hours, the treatment group was given PMZ pretreatment for 3 hours, and then GLU was administered for 24 hours. Cell viability was determined, cell morphology was observed by microscopy, reactive oxygen species levels and glutathione content were detected, and protein expression of P53, PTGS2, SLC7A11, and GPX4 was detected by western blotting. Network pharmacology: A total of 317 PMZ targets, 1934 AD genes, 125 intersection genes, and 18 core genes, including P53 and PTGS2. Gene Ontology enrichment analysis showed that the effect of PMZ on AD was mainly related to cell proliferation, inflammation, hypoxia, synaptic structure, plasma membrane, and oxidoreductase activity. Kyoto Encyclopedia of Genes and Genomes results showed neuroactive ligand-receptor interaction, cell senescence, cancer pathway, PI3K-AKT signal pathway, neurodegeneration, and HIF-1 signal pathway. In vitro experiments: PMZ improved the GLU-induced decrease in cell viability and morphological changes in hippocampal neurons. PMZ inhibited reactive oxygen species levels and increased glutathione content in injured hippocampal neurons. Up-regulated of P53, SLC7A11 and GPX4 expression, and inhibited expression of PTGS2. PMZ regulates the SLC7A11-GPX4 antioxidant system to protect hippocampal neurons from oxidative stress injury.

References

Jazvinscak Jembrek M, Orsolic N, Mandic L, Sadzak A, Segota S . Anti-Oxidative, Anti-Inflammatory and Anti-Apoptotic Effects of Flavonols: Targeting Nrf2, NF-κB and p53 Pathways in Neurodegeneration. Antioxidants (Basel). 2021; 10(10). PMC: 8533072. DOI: 10.3390/antiox10101628. View

Lee V, Goedert M, Trojanowski J . Neurodegenerative tauopathies. Annu Rev Neurosci. 2001; 24:1121-59. DOI: 10.1146/annurev.neuro.24.1.1121. View

Khan S, Barve K, Kumar M . Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease. Curr Neuropharmacol. 2020; 18(11):1106-1125. PMC: 7709159. DOI: 10.2174/1570159X18666200528142429. View

Naseri N, Wang H, Guo J, Sharma M, Luo W . The complexity of tau in Alzheimer's disease. Neurosci Lett. 2019; 705:183-194. PMC: 7060758. DOI: 10.1016/j.neulet.2019.04.022. View

Ou G, Che J, Dong J, Deng Y, Jiang X, Sun Y . Methylene blue targets PHD3 expression in murine microglia to mitigate lipopolysaccharide-induced neuroinflammation and neurocognitive impairments. Int Immunopharmacol. 2023; 120:110349. DOI: 10.1016/j.intimp.2023.110349. View

Korabecny J, Nepovimova E, Cikankova T, Spilovska K, Vaskova L, Mezeiova E . Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission. Neuroscience. 2017; 370:191-206. DOI: 10.1016/j.neuroscience.2017.06.034. View

Uddin M, Lim L . Glial cells in Alzheimer's disease: From neuropathological changes to therapeutic implications. Ageing Res Rev. 2022; 78:101622. DOI: 10.1016/j.arr.2022.101622. View

Butterfield D, Halliwell B . Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019; 20(3):148-160. PMC: 9382875. DOI: 10.1038/s41583-019-0132-6. View

Pinky , Neha , Salman M, Kumar P, Ahmed Khan M, Jamal A . Age-related pathophysiological alterations in molecular stress markers and key modulators of hypoxia. Ageing Res Rev. 2023; 90:102022. DOI: 10.1016/j.arr.2023.102022. View

10.

McClure R, Redha R, Vinson P, Pham W . A Robust and Scalable High-Throughput Compatible Assay for Screening Amyloid-β-Binding Compounds. J Alzheimers Dis. 2019; 70(1):187-197. PMC: 6943818. DOI: 10.3233/JAD-190316. View

11.

Lin X, Zhang H, Liu W, Dong X, Sun Y . Methylene Blue-Doped Carbonized Polymer Dots: A Potent Photooxygenation Scavenger Targeting Alzheimer's β-Amyloid. ACS Appl Mater Interfaces. 2023; 15(37):44062-44074. DOI: 10.1021/acsami.3c06948. View

12.

Tan X, Gong L, Li X, Zhang X, Sun J, Luo X . Promethazine inhibits proliferation and promotes apoptosis in colorectal cancer cells by suppressing the PI3K/AKT pathway. Biomed Pharmacother. 2021; 143:112174. DOI: 10.1016/j.biopha.2021.112174. View

13.

Sies H, Jones D . Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020; 21(7):363-383. DOI: 10.1038/s41580-020-0230-3. View

14.

Paroni G, Bisceglia P, Seripa D . Understanding the Amyloid Hypothesis in Alzheimer's Disease. J Alzheimers Dis. 2019; 68(2):493-510. DOI: 10.3233/JAD-180802. View

15.

Laube M, Kniess T, Pietzsch J . Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy-A Hypothesis-Driven Review. Antioxidants (Basel). 2016; 5(2). PMC: 4931535. DOI: 10.3390/antiox5020014. View

16.

Liu D, Xu Y . p53, oxidative stress, and aging. Antioxid Redox Signal. 2010; 15(6):1669-78. PMC: 3151427. DOI: 10.1089/ars.2010.3644. View

17.

Tripathy D, Sanchez A, Yin X, Luo J, Martinez J, Grammas P . Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. Front Aging Neurosci. 2013; 5:19. PMC: 3648692. DOI: 10.3389/fnagi.2013.00019. View

18.

Kisler K, Nelson A, Montagne A, Zlokovic B . Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017; 18(7):419-434. PMC: 5759779. DOI: 10.1038/nrn.2017.48. View

19.

Onukwufor J, Dirksen R, Wojtovich A . Iron Dysregulation in Mitochondrial Dysfunction and Alzheimer's Disease. Antioxidants (Basel). 2022; 11(4). PMC: 9027385. DOI: 10.3390/antiox11040692. View

20.

Karlsson D, Fallarero A, Brunhofer G, Mayer C, Prakash O, Mohan C . The exploration of thienothiazines as selective butyrylcholinesterase inhibitors. Eur J Pharm Sci. 2012; 47(1):190-205. DOI: 10.1016/j.ejps.2012.05.014. View